RHONE-POULENC RORER LOOKS EAST
One of the major prospects for future business for Rhone-Poulenc Rorer GmbH based in Germany lies in eastern Europe, executive chairman Jens Waldhof has said in Cologne. The company is to set up its own production facilities in the region.
Sales last year of R-PR GmbH, a subsidiary of the Franco-American Rhone- Poulenc Rorer group, rose 4.8% to 652 million Deutschemarks ($394.7 million), while operating profits rose from 59 million marks in 1990 to 149 million marks ($84.7 million).
The cost of concentration on the Cologne base (the home of Nattermann, the German drugmaker which Rhone-Poulenc acquired several years back) and the abandonment of the Eschwege and Bielefeld plants last year led to a negative net profits picture, with an after-tax figure of minus 7 million marks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze